TCBP Launches Compassionate Use Program For TCB008

5/15/24 8:37:39 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TCBP alert in real time by email

The Company's lead therapeutic will be available through a newly opened compassionate use program

EDINBURGH, Scotland, May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK.

Get the next $TCBP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCBP

Date	Price Target	Rating	Analyst

More analyst ratings

$TCBP
Leadership Updates

Live Leadership Updates

TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec
2/23/23 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TC BioPharm Announces New Chair of the Board, Arlene Morris
EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en
2/14/23 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm. Most recently she was with Loxo at Lilly, where
1/30/23 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm. "The ACHIEVE UK tria
10/30/24 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TCBP Responds to False Social Media Claim
TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchangeEDINBURGH, Scotland, Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange. The since deleted rumor stated th
10/25/24 9:45:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, United Kingdom and works closely with The Pirbright Institute, a leading ce
10/22/24 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$TCBP
Financials

Live finance-specific insights

TCBP Announces Shareholder Update Call on March 5th 2024
EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 10:00 am EST. Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provid
2/27/24 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TC BioPharm to Reschedule Shareholder Update Call and Webcast
Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it now plans to host its shareholder update call on Tuesday, February 21, 2023, at 12:00 p.m. ET. The call was originally scheduled for Monday, February 20, 2023, at 10:00 a.m. ET. Management intends to provide a comprehensive update on th
2/13/23 4:15:00 PM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TC BioPharm to Host Shareholder Update Call
Conference Call to be held on Monday, February 20th, 2023 at 10:00 am ET EDINBURGH, Scotland, Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the company will host a shareholder update call on Monday, February 20th, 2023, at 10:00 am EST. Management intends to provide a comprehensive update on the Company's clinical trial plan for its allogeneic gamma delta therapeutic in oncology
1/20/23 8:30:00 AM ET
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

TCBP Launches Compassionate Use Program For TCB008

Chat with this insight

Recent Analyst Ratings for
$TCBP

$TCBP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

SEC Form SC 13G filed by TC BioPharm (Holdings) plc

$TCBP
Leadership Updates

Live Leadership Updates

TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

TC BioPharm Announces New Chair of the Board, Arlene Morris

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

$TCBP
Market Insights

Live Market Insights

TCBP Doses 6th Patient In The ACHIEVE Study In Patients With Acute Myeloid Leukemia